Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma

被引：0
|
作者：
Oliver F Bathe
Scot Dowden
Francis Sutherland
Elijah Dixon
Charles Butts
David Bigam
Barb Walley
Dean Ruether
Scott Ernst
机构：
[1] University of Calgary,Department of Surgery
[2] University of Calgary,Department of Oncology
[3] University of Alberta,Department of Surgery
[4] University of Alberta,Department of Oncology
[5] London Regional Cancer Centre,Department of Oncology
来源：
BMC Cancer | / 4卷
关键词：
Liver Metastasis; Hepatic Resection; Radiofrequency Ablation; Preoperative Chemotherapy; Metastatic Colorectal Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Phase II study of neoadjuvant 5-FU plus leucovorin plus CPT-II in patients with resectable liver metastases from colorectal adenocarcinoma
    Bathe, OF
    Dowden, S
    Sutherland, F
    Dixon, E
    Butts, C
    Bigam, D
    Walley, B
    Ruether, D
    Ernst, S
    BMC CANCER, 2004, 4 (1)
  • [2] A phase II study of neoadjuvant irinatecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for resectable liver metastases from colorectal cancer.
    Bathe, OF
    Ernst, S
    Sutherland, F
    Dixon, E
    Koppel, J
    Butts, C
    Bigam, D
    Ruether, D
    Walley, B
    Dowden, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 286S - 286S
  • [3] A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
    Oliver F Bathe
    Scott Ernst
    Francis R Sutherland
    Elijah Dixon
    Charles Butts
    David Bigam
    David Holland
    Geoffrey A Porter
    Jennifer Koppel
    Scot Dowden
    BMC Cancer, 9
  • [4] A phase II experience with neoadjuvant irinotecan (CPT-II), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
    Bathe, Oliver F.
    Ernst, Scott
    Sutherland, Francis R.
    Dixon, Elijah
    Butts, Charles
    Bigam, David
    Holland, David
    Porter, Geoffrey A.
    Koppel, Jennifer
    Dowden, Scot
    BMC CANCER, 2009, 9
  • [5] Phase I study of CPT-11 and bolus 5-FU/l-leucovorin in patients with metastatic colorectal cancer
    Fujishima H.
    Kikuchi I.
    Miyanaga O.
    Ueda A.
    Baba E.
    Mitsugi K.
    Harada M.
    Nakano S.
    International Journal of Clinical Oncology, 2004, 9 (2) : 92 - 97
  • [6] Phase II trial of irinotecan (CPT-11) in patients with 5-FU resistant advanced colorectal cancer
    Vicent, JM
    Aparicio, J
    Lizon, J
    Molins, C
    Alonso, JD
    Gimenez-Arnau, JM
    Camps, C
    Segura, A
    Rizo, A
    Xarles, J
    ANNALS OF ONCOLOGY, 1998, 9 : 44 - 45
  • [7] A PHASE-I STUDY OF CPT-11, WEEKLY BOLUS 5-FU AND LEUCOVORIN IN PATIENTS WITH METASTATIC CANCER
    PARNES, HL
    TAIT, N
    CONLEY, B
    VANECHO, D
    ONCOLOGY REPORTS, 1995, 2 (06) : 1131 - 1134
  • [8] Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU):: A phase II study
    Antón, A
    Aranda, E
    Carrato, A
    Marcuello, E
    Massutti, B
    Cervantes, A
    Abad, A
    Sastre, J
    Fenández-Martos, C
    Gallén, M
    Díaz-Rubio, E
    Huarte, L
    Balcells, M
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (08): : 639 - 643
  • [9] A phase II study with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) in patients with metastatic colorectal cancer
    Destefanis, M
    Dalla Mola, A
    Ostellino, O
    Capello, C
    Milanesi, E
    Grillo, C
    Castiglione, F
    Venturino, A
    Porcile, G
    ANNALS OF ONCOLOGY, 2000, 11 : 67 - 67
  • [10] 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) versus CPT-11 followed by 5-FU/LV at relapse in patients with advanced colorectal carcinoma. Phase III randomized study
    Tsavaris, N.
    Kosmas, C.
    Skopelitis, E.
    Papadoniou, N.
    Polyzos, A.
    Zografos, G.
    Diamartis, N.
    Ntokou, A.
    Tsaousi, S.
    Sarantonis, I
    Adoniou, E.
    Gryniatsos, J.
    Felekouras, E.
    Papalambros, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 81 - 81
12345